Holen Sie sich die Stockscreener-App
0.689
0.14%
-0.002
Schlusskurs vom Vortag:
$0.691
Offen:
$0.69
24-Stunden-Volumen:
25,295
Relative Volume:
0.01
Marktkapitalisierung:
$5.14M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.28M
KGV:
-0.0495
EPS:
-13.91
Netto-Cashflow:
$-13.75M
1W Leistung:
+0.10%
1M Leistung:
-10.92%
6M Leistung:
-72.18%
1J Leistung:
-88.48%
1-Tages-Spanne:
$0.675
$0.71
1-Wochen-Bereich:
$0.65
$0.735
52-Wochen-Spanne:
$0.65
$7.50
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Firmenname
Pasithea Therapeutics Corp
Sektor
Branche
Telefon
(702) 514-4174
Adresse
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Vergleichen Sie KTTA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
0.6906 | 5.14M | 0 | -16.28M | -13.75M | -13.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.83 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.33 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.00 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.45 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
297.43 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Pasithea Therapeutics Corp Aktie (KTTA) Neueste Nachrichten
What analysts say about Pasithea Therapeutics Corp. Equity Warrant stockExceptional stock performance - Jammu Links News
What analysts say about Pasithea Therapeutics Corp. stockConsistently exceptional gains - Jammu Links News
Why Pasithea Therapeutics Corp. stock attracts strong analyst attentionROI Focused Stock Calls - Newser
How Pasithea Therapeutics Corp. Equity Warrant stock performs during market volatility200 Percent Gain Alert - Newser
How Pasithea Therapeutics Corp. stock performs during market volatilityAI Powered Stock Call - Newser
What makes Pasithea Therapeutics Corp. Equity Warrant stock price move sharplyHigh Return Investment Tips - Newser
Why Pasithea Therapeutics Corp. Equity Warrant stock attracts strong analyst attentionFree Smart Investment Opportunities - Newser
What makes Pasithea Therapeutics Corp. stock price move sharplyDaily Stock Radar - Newser
Pasithea Sets Deadline for Shareholder Proposals - The Globe and Mail
Pasithea Therapeutics schedules 2025 annual meeting for September 3 By Investing.com - Investing.com Nigeria
Pasithea Therapeutics schedules 2025 annual meeting for September 3 - Investing.com
Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board - GlobeNewswire
Nature Journal Author Joins Pasithea to Advance Revolutionary IBD Treatment Research - Stock Titan
Pasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s Elated - MSN
Pasithea reports promising phase 1 results for cancer drug By Investing.com - Investing.com South Africa
Pasithea reports promising phase 1 results for cancer drug - Investing.com
Pasithea Therapeutics Reports Promising Interim Results for PAS-004 in Phase 1 Trial for Refractory Solid Tumors at ASCO 2025 - Nasdaq
Pasithea Therapeutics Presents Updated Interim Data from - GlobeNewswire
Breakthrough Cancer Drug Shows 15% Tumor Shrinkage in Melanoma and Pancreatic Cancer Patients in Phase 1 Trial - Stock Titan
Pasithea’s PAS-004 shows promise in inflammatory disease study - Investing.com Australia
Pasithea Therapeutics Announces Preclinical Data That Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases - marketscreener.com
Pasithea Therapeutics Reports Promising Preclinical Data for PAS-004 as a Novel MEK Inhibitor for Inflammatory Diseases - Nasdaq
Pasithea Therapeutics Announces Preclinical Data that Shows - GlobeNewswire
Breakthrough: Novel IBD Drug Outperforms FDA-Approved Treatment in Targeting Key Inflammation Pathway - Stock Titan
Neurofibromatosis Type 1 Market Set to Witness Significant Growth During the Study Period (2020–2034) Driven by Advances in Treatment | DelveInsight - GlobeNewswire Inc.
Pasithea to commence Phase I/Ib trial of neurofibromatosis type 1 therapy - Yahoo Finance
Pasithea Therapeutics CEO sells shares worth $792 - Investing.com
Pasithea Therapeutics Announces Initiation Of Phase 1/1B Study Of Pas-004 In Adult Nf1 Patients And Activation Of First Clinical Trial Site - marketscreener.com
Pasithea Therapeutics Announces Initiation of Phase 1/1B - GlobeNewswire
Phase 1/1b Trial: Pasithea's Once-Daily NF1 Drug Could Outperform Current Treatments - Stock Titan
Pasithea Therapeutics Raises $6.3 Million in Stock Offering - TipRanks
Pasithea Therapeutics Closes $5 Million Public Offering to Advance Development of PAS-004 for Neurofibromatosis and Cancer Indications - Nasdaq
Pasithea Therapeutics Announces Closing of $5 Million Public Offering - GlobeNewswire
Pasithea Therapeutics 3.57M share Secondary priced at $1.40 - Yahoo Finance
Pasithea Therapeutics Announces Pricing Of $5 Million Public Offering - marketscreener.com
Pasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s Elated By Stocktwits - Investing.com India
Pasithea Therapeutics Prices $5 Million Public Offering - marketscreener.com
Pasithea Therapeutics announces interim data from Phase 1 trial of PAS-004 - TipRanks
Pasithea Therapeutics Announces Pricing of $5 Million Public Offering - The Manila Times
Pasithea Therapeutics (KTTA) Skyrockets: Stock Soars Over 115% in Morning Trade - apnakal
$5M Public Offering: Pasithea Therapeutics Advances MEK Inhibitor Drug for Rare Disease Treatment - Stock Titan
Finanzdaten der Pasithea Therapeutics Corp-Aktie (KTTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pasithea Therapeutics Corp-Aktie (KTTA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Marques Tiago | Chief Executive Officer |
May 12 '25 |
Sale |
0.82 |
960 |
792 |
40,001 |
0.86%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):